Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 19620962.
- Also identified by DOI 10.1038/nm.1989 and PMC identifier 2723179.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5-HIV-1 vectors in the Merck STEP trial remain unclear. We find that Ad5 serostatus does not predict Ad5-specific CD4(+) T cell frequency, and we did not observe durable significant differences in Ad5-specific CD4(+) T cells between Ad5-seropositive and Ad5-seronegative subjects after vaccination. These findings indicate no causative role for Ad5-specific CD4(+) T cells in increasing HIV-1 susceptibility in the STEP trial.
Medical subject headings
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Adenoviridae
- Antibodies, Viral
- CD4-Positive T-Lymphocytes
- T-Cell Antigen Receptor Specificity